Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04895020
Other study ID # 9-HPV-3003
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date May 28, 2021
Est. completion date May 2026

Study information

Verified date April 2024
Source Shanghai Bovax Biotechnology Co., Ltd.
Contact Huakun Lv
Phone 13588458021
Email hklv@cdc.zj.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase 3 study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese females aged 9 to 45 years


Description:

This study (protocol 9-HPV-3003) is an immunogenicity and safety study in the subjects (9-19 years of age) who received the 9-valent HPV recombinant vaccine compared with the subjects (20-45 years of age). In this study, we will assess whether the immunogenicity of the 9-valent HPV vaccine given 3-dose schedule in the subjects (9-19 years of age) in noninferior to that in the subjects (20-45 years of age) receiving 3 doses, while assessing the safety of this vaccine.


Recruitment information / eligibility

Status Recruiting
Enrollment 1200
Est. completion date May 2026
Est. primary completion date January 13, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 9 Years to 45 Years
Eligibility Inclusion Criteria: Inclusion Criteria for the first stage: 1. Healthy Chinese females aged 9 to 45 years; Provide legal identification; 2. The subject voluntarily agrees to enroll in this study. If the subject is a minor, both the subject and subject's legal guardian should voluntarily agree to enroll in this study and sign an informed consent form; 3. Be able to understand the study procedures and promise to participate in regular follow-ups under the requirements; 4. Had a negative urine pregnancy test on the day of enrollment, among the subjects of childbearing age; Not in the duration of breast-feeding and no birth plan within 7 months; According to the investigator's judgment that there is no possibility of pregnancy at that time: subjects have taken effective contraception, or asexual life after the last menstrual period, or use IUD, or had undergone ligation; subjects agree to continue take effective contraception such as taking OCS and condom use; 5. No fever symptoms on the day of enrollment (aged> 14 years old, axillary temperature<37.3°C; aged = 14 years old, axillary temperature<37.5°C ); Inclusion Criteria for the second stage: 6. Received all 3 doses of trial vaccination; 7. Subjects aged 9 to 19 years at the first stage. Exclusion Criteria: 1. Received marketed HPV vaccine or plan to receive marketed HPV vaccine during this study period or have enrolled in HPV vaccine clinical trials; 2. History of positive test to HPV, history of cervical cancer (e.g. abnormal screening test results, abnormal cervical biopsy results, including CIN, AIS, and cervical cancer) or history of hysterectomy (vaginal or abdominal radical hysterectomy), or history of pelvic radiotherapy; History of genital diseases related to HPV infection (e.g. uterine peristalsis, VIN, VAIN, AIN, and related cancers); History of STDs, including syphilis, gonorrhea, genital herpes, Mycoplasma genitalium, Lymphgranuloma Venereum, granuloma inguinale, etc.; 3. Known allergy to any vaccine components or history of severe allergic diseases requiring treatment, including shock, laryngeal edema, urticarial, Henoch-Schonlein purpura, Arthus reaction, etc.; 4. Had primary or acquired immunodeficiency such as HIV, SLE, JRA, etc. or received immunosuppressive treatment within one month before study such as long-term glucocorticoid use(=2mg per kg per day, lasted more than two wks), or plan to receive such treatment from day 0 to month 7 after the last dose; 5. Had chronic diseases or congenital malformations, which might interfere with the process and completion of this study, such as Down Syndrome, heart diseases, liver diseases, chronic diabetes complications, and malignant tumor; 6. Enrolling or plan to enroll in other clinical trials (drug or vaccine); 7. Had infectious diseases such as TB, viral hepatitis, and/or HIV infection; 8. Had convulsions, epilepsy, encephalopathy, and mental illness or family history; 9. With prohibitive contraindications such as Thrombocytopenia or coagulopathy; 10. Asplenic, functionally asplenic, or splenectomy caused by any condition; 11. Within 3 days prior to vaccination, have an acute disease or are in the acute attack of a chronic disease or have used antipyretic, analgesic and anti-allergic drugs (such as: acetaminophen, ibuprofen, aspirin, loratadine, ceti Rizine, etc.); 12. Receipt of inactivated or recombinant vaccines within 14 days, live vaccines within 28 days; 13. Receipt of immune globulin or blood-related products within 3 months; or plan to receive such products during this study period; 14. Had fever symptoms within 24 hours on the first day (aged> 14 years old, axillary temperature = 37.3°C; aged = 14 years old, axillary temperature =37.5°C ); 15. Untreated/uncontrolled hypertension before vaccination (aged 9 to 17 years: systolic BP>120mmHg and/or diastolic BP>80mmHg; aged more than 18 years: Systolic BP=140mmHg and/or diastolic BP =90mmHg); 16. Plan to permanently relocate from the area before the end of the study or leave the local area for a long time during the study visit (affecting the scheduled visit time); 17. According to the investigator's judgment, the subject has any condition may interfere with process of evaluation or participating in this study cannot guarantee the object's maximum benefit.

Study Design


Intervention

Biological:
9-valent HPV vaccine
9-valent HPV recombinant vaccine (Hansenula Polymorpha) All subjects aged 9 to 45 years received 3 doses of 9v HPV vaccine at 0,2,6 month scehdule

Locations

Country Name City State
China Huakun Lv Hangzhou

Sponsors (2)

Lead Sponsor Collaborator
Shanghai Bovax Biotechnology Co., Ltd. Chongqing Bovax Biopharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Number of AE within 30 minutes after each dose Adverse events reported within 30 minutes after each dose 30 mins after each dose
Other Number of SAE within 7days after each dose Solicited adverse events reported between day 0 to day 7 after each dose day 0 to day 7 after each dose
Other Number of unsolicited adverse events within 30days after each dose Unsolicited adverse events reported between day 0 to day 30 after each dose day 0 to day 30 after each dose
Other Number of all SAE during the study period Serious adverse events reported during the study period Stage 1: from month 6 to month 12 after the last dose; Stage 2: 6 month after receiving the whole vaccine schedule to 60 month after the 1st dose
Other Number and rate of pregnancy events Pregnant event and pregnant outcome reported during the study period Stage 1: from month 6 to month 12 after the last dose; Stage 2: 9-to-19-year-old subjects received 3 doses vaccinations, 6 month after receiving the whole vaccine schedule to 60 month after the 1st dose
Primary The primary immunogenicity objective The primary outcome measure for assessing vaccine immunogenicity, among subjects aged between 9 and 45, is the results of seroconversion rate of neutralizing antibodies after immunization in pre-immune negative subjects from 30 days after the last dose (3 doses schedule, Month 7) to HPV 6, 11, 16, 18, 31, 33, 45, 52 , and 58. 30 days after the last dose(3 doses schedule)
Secondary Number of patients with postive antibodies after the whole schedule vaccination from the former negative subjects The secondary outcome measure for assessing vaccine immunogenicity, among subjects aged between 9 and 45, is the geometric mean titer (GMT) from 30 days after the last dose (3 doses schedule, Month 7) to HPV 6, 11, 16, 18, 31, 33, 45, 52 , and 58. 30 days after the last dose(3 doses schedule)
Secondary Rate of seroconversion among the patient aged 9-26 after the whole schedule vaccination To assess vaccine immunogenicity among the subjects aged between 9 and 26, is the seroconversion rate of neutralizing antibodies and the GMT from 30 days after the last dose (3 doses schedule, Month 7) to HPV 6, 11, 16, 18, 31, 33, 45, 52 , and 58. 30 days after the last dose(3 doses schedule)
Secondary GMT and seropositive rate of HPV in the 9-19 age group after 60-month follow-up After receiving all 3 doses vaccinations, the subjects aged 9 to 19 years will be followed for 60 month (Month 12/24/36/48/60) after first vaccination to assess the GMT and seropositive rate (4-fold-increase) to HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58. Day 1 to 60 months post vaccination 3
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT03367871 - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer Phase 2
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT04806945 - A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer Phase 3
Active, not recruiting NCT04185389 - Long-Term Follow-Up of HPV FOCAL Participants
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Completed NCT05120167 - Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy N/A
Recruiting NCT05483491 - KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Phase 1
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT05862844 - Promise Women Project N/A
Recruiting NCT04934982 - Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2) N/A
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Terminated NCT04864782 - QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer Phase 2/Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A